Culture

Even small levels of nitrate in drinking water results in smaller babies

The more nitrate there is in mothers' drinking water, the smaller the babies they give birth to. But alarmingly, the declining birth weight can also be registered when the women are exposed to nitrate levels below the EU's threshold of 50 milligrams of nitrate per litre.

This is shown by a register-based study of more than 850,000 births in Denmark carried out in a Danish-American partnership led by Professor Torben Sigsgaard from the Department of Public Health at Aarhus University and Professor Leslie Stayner and Dr. Vanessa Coffman from the Division of Epidemiology and Biostatistics at the University of Illinois at Chicago, School of Public Health.

On the basis of Danish registry data, the research group concluded that babies born to mothers whose drinking water contains between 25 and 50 milligrams of nitrates per litre - i.e. from half of the current threshold value up to the maximum limit - on average weigh ten grams less than babies born to mothers with smaller amounts of nitrate in the tap water. Not only did the babies weigh less, they were also slightly shorter, while their head size was unaffected by the amount of nitrate - which is the form of nitrogen run off from the agricultural sector that most frequently appears in groundwater.

According to Professor Torben Sigsgaard from Aarhus University, it is difficult to say whether we should be concerned about public health in areas with high amounts of nitrate:

"The difference in body length and weight doesn't sound like much at first as it's on average only ten grams, but this is not insignificant if the newborn also begins life as underweight for other reasons. Birth weight is generally recognised as having a life-long impact on a person's health and development," says Torben Sigsgaard.

"There is no doubt that the results of the study challenge the threshold value that is in place throughout the Western world, and that any changes will be a bit like turning around a supertanker. But it's important to discuss these results," he adds with reference to the WHO, EU and American authorities who all view drinking water as harmful when the content of nitrates is higher than fifty milligrams per litre.

The study was initiated because it has long been known that very high nitrate concentrations may lead to people being exposed to nitrite. This inhibits the body's ability to absorb oxygen and can lead to the dangerous blue-baby syndrome, or methemoglobinemia to give it its medical name. Nitrate in drinking water is also suspected of causing other chronic diseases, including bowel cancer. Research has also documented how, depending on local geological and geochemical conditions in theearth, the fertiliser used in agriculture more or less percolates down to the groundwater.

"With the study, we've established that there is a need to explore the effect of the low nitrate concentrations in the drinking water, if we're to assess the adequacy of the current threshold values - and this is possible thanks to the unique Danish registers. It wouldn't be possible to carry out corresponding studies on the basis of US data alone, because such data simply doesn't exist," says Torben Sigsgaard.

Credit: 
Aarhus University

A better treatment for sickle cell disease

image: Doctoral student Tanmay Mathur (left) and Dr. Abhishek Jain review photos of blood cells formed on the organ-on-a chip in their lab.

Image: 
Texas A&M University College of Engineering

Sickle cell disease is the most prevalent inherited blood disorder in the world, affecting 70,000 to 100,000 Americans. However, it is considered an orphan disease, meaning it impacts less than 200,000 people nationally, and is therefore underrepresented in therapeutic research.

A team led by Abhishek Jain from the Department of Biomedical Engineering at Texas A&M University is working to address this disease.

"I'm trying to create these new types of disease models that can impact health care, with the long-term goal of emphasizing on applying these tools and technologies to lower health care costs," said Jain, assistant professor in the department. "We strategically wanted to pick up those disease systems which fall under the radar in orphan disease category."

Jain's research is in organ-on-a-chip, where cells from humans can be grown on USB-sized devices to mimic the way the organ would work inside the body. This sort of system is ideal for testing new drug treatments, as drugs cannot be tested on humans, and animal models have not shown to be a good representation of how a patient and disease would interact with a treatment. For sickle cell disease patients, the organ-on-a-chip would also be beneficial because patients can present with mild to severe cases.

Jain works with Tanmay Mathur, a fourth-year doctoral student who trained as a chemical engineer in his undergraduate years. His research focused on microfabrication techniques and simulations, skills he said merged well into the organ-on-a-chip research he now performs in Jain's lab. The team collaborates closely with the Texas Medical Center in Houston.

The work was recently published in the journal Bioengineering & Translational Medicine. Their paper builds off a 2019 publication in the journal Lab on Chip, where the team demonstrated that endothelial cells (cells that line the blood vessels) could be used to model the disease physiology of a patient without having to stimulate the model to perform differently than a healthy vessel.

"Traditionally these cells were not used for disease modeling, so in that way our approach is very novel," Mathur said. "We are one of first to harness these cells and employed them in disease modeling research."

Mathur and Jain demonstrate that these models can be used to differentiate between patients. The first step: build a blood vessel that mimics a patient's vessel. For that the team would need two components -- patient blood and endothelial cells. Collecting the blood involved a simple blood draw. They faced a challenge with the endothelial cells, however. They would need to take a biopsy of the cells or use stem cells to grow their own, neither of which was ideal.

Then they found the answer was in the blood.

"What we learned is within blood samples are some endothelial cells also circulating," Jain said. "We call them blood outgrowth endothelial cells that we can harness very easily. That's what is new about this work. You can get those cells, grow them so that's there's enough in number and then you can make blood vessels."

Now that they could build the vessels, the next step was to see if these models would show how the disease has various biological impacts in different patients. Again, the goal was to be able to test treatments on these models, so the closer they mimiced their human patient, the better.

"We're able to differentiate a very severe sickle cell patient in terms of their phenotype from very mild patients," Mathur said. "Moving forward, we can take a larger population of any sickle cell disease patients and assess them using our organ-chip technology and then categorize them into different groups based on symptoms."

Their findings indicate that these organs-on-a-chip could lead to patient-centric, personalized treatment, improving how clinicians approach this and other cardiovascular diseases.

"When you take it to the field, now it can become a predictive device," Jain said. "Now you do not have to know whether the patient is mild or severe, you can test for that. You can predict if patient is serious and can dictate their therapeutic needs."

The next step is to continue to expand the patient cohort to collect more results. A long-term goal would be to use the patient information collected to develop a database to better predict disease progression.

"You take a history of a lot of these patients and their cardiovascular health with this device, and you can predict which patient might have better chance of having a stroke and you start treating them early on," Jain said.

Mathur said even with future challenges, he looks forward to continuing their research.

"I think even though it may take 10, 15 years, we will at least push forward some of the research that we're doing and get it out in the clinical field," he said. "We are one of the only groups in the world that have started this field of personalized treatment. I feel that our impact is pretty high, and I'm sure we will be able to expand the same treatment to other cardiovascular diseases and attract more attention and deeper insights into the biology that we are looking at."

Credit: 
Texas A&M University

New drug candidate against COVID-19

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, arrived one year ago and turned our lives upside-down.

While worldwide vaccination programs are currently ongoing, we do not yet know for how long the vaccine will provide immune protection against infection, and if the currently approved vaccines can provide protection against the emerging virus variants.

In addition, it appears that vaccines cannot prevent illness for people who have already been infected. In contrast to vaccines, there are currently no effective drugs that act against the virus SARS-CoV-2.

New research by Associate Professor Jasmin Mecinovic and co-workers from the Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, now presents a compound that might provide a basis for the development of drugs against COVID-19.

The work has been recently published in Chemical Communications.

- Our approach is based on mimicking Nature, and the idea is to prevent the virus from entering the body's cells. If the virus does not enter the cells, it cannot survive. Instead, the immune system destroys the viral particles, thus preventing an infection, explains Jasmin Mecinovic.

SARS-CoV-2 belongs to the family of coronaviruses, which are named after their characteristic crown shaped envelope that shields its RNA from being damaged. This crown is made up out of viral spike proteins, which act as the lock-picks used by the virus to break into a host cell.

The SARS-CoV-2 spike protein specifically interacts with an enzyme, called ACE2 receptor, to initiate cell entry and infection.

The ACE2 receptor is found on the surface of cells in many different tissues and is especially common in the lungs. For this reason, SARS-CoV-2 infection leads to (severe) respiratory disease symptoms for many people.

Mecinovic and colleagues have found that peptides (a small part of protein), made to look exactly like the ACE2 receptor can act as a decoy and prevent binding of the of the SARS-CoV-2 spike protein.

- This suggests that molecular decoys based on the ACE2 receptor might be an effective therapeutic to prevent infection by the virus, says PhD student Marijn Maas, the first author of the article.

- Getting a new drug to the market is a long journey. Next step is to continue studying our synthetic peptide - for example by making variations of it to see if we can improve its potency, says Jasmin Mecinovic.

Credit: 
University of Southern Denmark

Black hole shows magnetic fields surrounding it are strong enough to resist gravity

image: Polarised view of the black hole in M87. The lines mark the orientation of polarisation, which is related to the magnetic field around the shadow of the black hole.

Image: 
© EHT Collaboration

The Event Horizon Telescope (EHT) collaboration, a multinational team of over 300 scientists including two astrophysicists from the University of the Witwatersrand (Wits University), has revealed today a new view of the massive object at the centre of the M87 galaxy: how it looks in polarised light.

This is the first time astronomers have been able to measure polarisation, a signature of magnetic fields, this close to the edge of a black hole. The observations are key to explaining how the M87 galaxy, located 55 million light-years away, is able to launch energetic jets from its core.

"We are now seeing the next crucial piece of evidence to understand how magnetic fields behave around black holes, and how activity in this very compact region of space can drive powerful jets that extend far beyond the galaxy," says Monika Mo?cibrodzka, Coordinator of the EHT Polarimetry Working Group and Assistant Professor at Radboud Universiteit in the Netherlands.

"This work is a major milestone: the polarisation of light carries information that allows us to better understand the physics behind the image we saw in April 2019, which was not possible before," explains Iván Martí-Vidal, also Coordinator of the EHT Polarimetry Working Group and GenT Distinguished Researcher at the Universitat de València, Spain. He adds that "unveiling this new polarised-light image required years of work due to the complex techniques involved in obtaining and analysing the data."

Professor Roger Deane, SARAO/NRF Chair in Radio Astronomy at Wits and his postdoctoral researcher, Dr Iniyan Natarajan, are the only two scientists in the EHT collaboration that are based on the African continent. On 10 April 2019, the collaboration released the first ever image of a black hole, revealing a bright ring-like structure with a dark central region -- the black hole's shadow. Today's results reveal that a significant fraction of the light around the M87 black hole is polarised.

"When unpolarised, the oscillations of the electromagnetic fields have no preferred direction. Filters such as polarised sunglasses or magnetic fields in space, preferentially let the oscillations in one direction pass through, thereby polarising the light. Thus, the polarised-light image illuminates the structure of the magnetic fields at the edge of the black hole," says Natarajan, who was part of the EHT Polarimetry Working Group.

Black holes have long been known to launch powerful jets of energy and matter far out into space. Astronomers have relied on different physical models of how matter behaves near the black hole to better understand this process. The jet emerging from M87's core extends at least 5000 light-years from its centre, the process behind which is still unexplained.

The observations suggest that the magnetic fields at the black hole's edge are strong enough to push back on the hot gas and help it resist gravity's pull. Only the gas that slips through the field can spiral inwards to the event horizon.

To observe the heart of the M87 galaxy, the collaboration linked eight telescopes around the world to create a virtual Earth-sized telescope, the EHT. The impressive resolution obtained with the EHT is equivalent to that needed to measure the size of a cricket ball on the surface of the Moon.

This setup allowed the team to directly observe the black hole shadow and the ring of light around it, with the new polarised-light image clearly showing that the ring is magnetised. The results are published today in two separate papers in The Astrophysical Journal Letters by the EHT collaboration.

"Peering as close as we can to the edge of black holes using cutting-edge techniques is precisely the sort of challenge we relish here at Wits," says Deane, Founding Director of the newly approved Wits Centre for Astrophysics. "We are in a golden era for radio astronomy, and our involvement in projects like the Event Horizon Telescope and the Square Kilometre Array is at the centre of our plan to carry out fundamental research, and train world-class postgraduate students who will become the leading African scientists of tomorrow."

Natarajan was involved in simulating the black hole polarisation observations and was also part of the efforts to calibrate and generate the polarised image. Deane and Natarajan have also written one of the software packages that is being used to simulate black hole observations within the EHT collaboration.

"Our collaboration developed new techniques for analysing the polarisation data, which were validated on simulations before being applied to real observations," says Natarajan.

"Such challenging projects provide the opportunity to develop techniques which later find wider applicability in the community in ways which can pleasantly surprise us."

Credit: 
University of the Witwatersrand

Astronomers image magnetic fields at the edge of M87's black hole

image: The lines mark the orientation of polarisation, which is related to the magnetic field around the shadow of the black hole.

Image: 
© EHT Collaboration

AMHERST, Mass. - An international team of astronomers, including University of Massachusetts Amherst professors Gopal Narayanan and Peter Schloerb, has just revealed a new view of the massive black hole at the center of a galaxy located 55 million light-years away, known as the M87 galaxy. This new image, captured by the Event Horizon Telescope (EHT) collaboration, shows how M87 looks in polarized light, and is published today in two papers appearing in The Astrophysical Journal (links here and here). It is the first time astronomers have been able to measure polarization, a signature of magnetic fields, this close to the edge of a black hole. The observations are key to explaining how the M87 galaxy is able to launch energetic jets from its core.

"There is a super-massive black hole at the center of almost every galaxy," Narayanan explains. These black holes power the galactic nuclei, which often launches high energy jets from the central parts of the galaxy. Understanding the physics connecting super-massive black holes and galactic jets has been difficult. That is where light polarization comes in.

Light becomes polarized when it goes through certain filters, like the lenses of polarized sunglasses, or when it is emitted in hot regions of space that are magnetized. In the same way polarized sunglasses help us see better by reducing reflections and glare from bright surfaces, astronomers can sharpen their vision of the region around the black hole by looking at how the light originating from there is polarized. Specifically, polarization allows astronomers to map the magnetic field lines present at the inner edge of the black hole. "Magnetic fields and jets have previously been mapped," says Narayanan, "but at lower resolution. Now we can zoom in to the energetic launching regions of these jets with incredible resolution and map the jets in a way that has never been done before."

"We are now seeing the next crucial piece of evidence to understand how magnetic fields behave around black holes, and how activity in this very compact region of space can drive powerful jets that extend far beyond the galaxy," says Monika Mo?cibrodzka, coordinator of the EHT Polarimetry Working Group and assistant professor at Radboud Universiteit in the Netherlands

Astronomers have relied on different models of how matter behaves near the black hole to better understand this process. But they still don't know exactly how jets larger than the galaxy are launched from its central region, nor how exactly matter falls into the black hole. With the new EHT image of the black hole and its shadow in polarized light, astronomers managed for the first time to look into the region just outside the black hole where the interplay between matter flowing in and being ejected out happens. "What's particularly notable about this observation," says Schloerb, "is that by measuring polarization you're really getting at the properties of the magnetic field, which is so important because it helps us understand the basic physics of how galaxies evolve."

To observe the heart of the M87 galaxy, the collaboration linked eight telescopes around the world, including the Large Millimeter Telescope (LMT), jointly operated by UMass and the country of Mexico, and the largest of its kind. Narayanan, who leads UMass's EHT team, built the radio-astronomical receiver for the LMT that helped to gather the data on the M87's black hole. The impressive resolution obtained with the EHT is equivalent to that needed to measure the length of a credit card on the surface of the Moon.

This setup allowed the team to directly observe the black hole shadow and the ring of light around it, with the new polarized-light image clearly showing that the ring is magnetized. The results are published today in two separate papers in The Astrophysical Journal Letters by the EHT collaboration. The research involved over 300 researchers from multiple organizations and universities worldwide.

"Unveiling this new polarized-light image required years of work due to the complex techniques involved in obtaining and analyzing the data," says Iván Martí-Vidal, coordinator of the EHT Polarimetry Working Group and GenT Distinguished Researcher at the Universitat de València, Spain.

"The thing I'm most fascinated about is the follow-up," says Narayanan. "We have even more sensitive receivers now, and with more sensitive instruments we can pull out more details in the magnetic fields. There's even more exciting data and analysis ahead."

Credit: 
University of Massachusetts Amherst

New study finds false memories can be reversed

Rich false memories of autobiographical events can be planted - and then reversed, a new paper has found.

The study highlights - for the first time - techniques that can correct false recollections without damaging true memories. It is published by researchers from the University of Portsmouth, UK, and the Universities of Hagen and Mainz, Germany.

There is plenty of psychological research which shows that memories are often reconstructed and therefore fallible and malleable. However, this is the first time research has shown that false memories of autobiographical events can be undone.

Studying how memories are created, identified and reversed could be a game changer in police and legal settings, where false memories given as evidence in a courtroom can lead to wrongful convictions.

According to Dr Hartmut Blank, co-author of the research from the University of Portsmouth's Department of Psychology, "believing, or even remembering something that never happened may have severe consequences. In police interrogations or legal proceedings, for instance, it may lead to false confessions or false allegations, and it would be highly desirable, therefore, to reduce the risk of false memories in such settings.

"In this study, we made an important step in this direction by identifying interview techniques that can empower people to retract their false memories."

The researchers recruited 52 participants for a study on 'childhood memories' and with the help of parents, they implanted two false negative memories that definitely didn't happen, but were plausible. For example getting lost, running away or being involved in a car accident.

Along with two true events, which had actually happened, participants were persuaded by their parents that all four events were part of their autobiographical memory.

The participants were then asked to recall each event in multiple interview sessions. By the third session, most believed the false events had happened and - similar to previous research - about 40 per cent had developed actual false memories of them.

The researchers then attempted to undo the false memories by using two strategies.

The first involved reminding participants that memories may not always be based on people's own experience, but also on other sources such as a photograph or a family member's narrative. They were then asked about the source of each of the four events.

The second strategy involved explaining to them that being asked to repeatedly recall something can elicit false memories. They were asked to revisit their event memories with this in mind.

The result, according to Dr Blank, was that "by raising participants' awareness of the possibility of false memories, urging them to critically reflect on their recollections and strengthening their trust in their own perspective, we were able to significantly reduce their false memories. Moreover, and importantly, this did not affect their ability to remember true events.

"We designed our techniques so that they can principally be applied in real-world situations. By empowering people to stay closer to their own truth, rather than rely on other sources, we showed we could help them realise what might be false or misremembered - something that could be very beneficial in forensic settings."

Credit: 
University of Portsmouth

Stay on track! Support system to help the visually impaired navigate tactile paving

image: Overview of the proposed system, comprising a depth camera, a small circuit board, and earphones to issue auditory warnings when obstacles are present. The new image processing algorithm can dynamically generate thresholds to better detect tactile paving.

Image: 
Shibaura Institute of Technology (SIT)

Sight is by far the sense that we humans use the most when navigating an environment. When those who are blind or visually impaired walk alone, they put themselves at great risk of falling or colliding with obstacles, especially when traversing new places. Unfortunately, the number of visually impaired people throughout the world is likely to increase in the near future because of the rapidly aging population. Thus, there is an urgent need for innovative and cost-effective solutions to help visually impaired people navigate safely.

A promising strategy that was first implemented in Japan and then replicated throughout the world is called tactile paving. Inspired by Braille, the reading system of the blind, tactile paving essentially consists of placing textured tiles to form a guiding path that can be felt through the sole or with a cane. With the advent of modern digital technology, researchers worldwide are trying to implement camera-based support systems to help visually impaired or blind people find and stay on tactile paving paths, as well as warn the user of impending obstacles.

However, many challenges remain unsolved in currently available options, which results in limited applicability. "Many existing camera-based approaches for detecting tactile paving depend on filtering color information with fixed thresholds, though this strategy is not reliable in contexts with variable lighting conditions that can cause large changes in color," explains Associate Professor Chinthaka Premachandra from Shibaura Institute of Technology (SIT), Japan. "This problem is made worse by the fact that different places use different color schemes for their tactile paving," he adds.

In an effort to tackle these problems efficiently, Dr. Premachandra and his team have developed a new image processing algorithm that can more accurately detect tactile paving. As described in their latest study published in IEEE Access, their proposed support system consists of a forward-facing depth camera worn around the chest that is connected to a small microcomputer board roughly the size of a credit card. The board continuously executes the image processing algorithm on the data captured by the camera and detects tactile paving. If an obstacle on the tactile paving is detected, the system warns the user through earphones.

The most important part of the system--the image processing algorithm--was the focus of the study. The team's objective was to make the detection of tactile paving independent of pre-defined color thresholds. To this end, they first employed a widely studied technique called the Hough line transform. With it, straight lines in any image can be found, therefore making it relatively easy to find the borders of the tactile paving. Once the tentative borders of the tactile paving are found, the algorithm looks at the distribution of colors in a small area near the center of the path. Through statistical analyses, it determines an appropriate threshold for the current frame to generate an appropriate 'image mask' that marks the tactile paving. Finally, after a few final adjustments to reduce noise are made, the result is an image in which the tactile paving is clearly identified.

The scientists tested their system experimentally using nearly a thousand pictures of tactile paving from around the world. Excited about the promising results, Dr. Premachandra remarks: "The proposed system correctly detected tactile paving 91.65% of the time in both indoor and outdoor environments under varying lighting conditions, which is a markedly higher accuracy than previous camera-based methods with fixed thresholds." Another notable advantage of the system is that it can be implemented in small microprocessor-based circuits, unlike other strategies that required the user to carry a laptop.

With eyes set on the future, Dr. Premachandra and his team are working on increasing the system's processing speed and further improving its accuracy, especially under extreme lighting conditions such as those in the nighttime and when under very bright lights. Hopefully, future progress in cost-effective and practical support systems will make it safer for visually impaired people to walk alone, giving them more freedom and confidence to go to new places.

Credit: 
Shibaura Institute of Technology

'Silencing' protein to weaken COVID-19

image: Interfering with nsp14 binding and with the nsp10-nsp14 protein complex is the aim of the most recent ITQB NOVA research in COVID-19

Image: 
ITQB NOVA

When invaded by a virus, our body cells launch an alert to neighboring cells to increase their antiviral defenses to prevent the infection from spreading. Some viruses, however, manage to bypass this system by mimicking the host's RNA, preventing them from being detected by the infected cell and avoiding this alert. In the case of SARS-CoV-2, this mimicking uses a protein known as nsp14. This protein is also very important for virus multiplication, a task which is facilitated by its binding to the nsp10 protein, resulting in a protein complex. Interfering with nsp14 binding and with the nsp10-nsp14 protein complex is the aim of the most recent ITQB NOVA research in COVID-19, led by researchers Margarida Saramago, Rute Matos and Cecília Arraiano.

The researchers began by performing the biochemical characterization of the nsp10-nsp14 protein complex, a known therapeutic target. "For the first time, it was possible to identify the amino acids which must be targeted in order to silence this complex", explains Rute Matos. The silencing of nsp14 also "makes it easier for the organism to identify the virus' messenger RNA and to activate the immune system before it replicates", adds fellow researcher Margarida Saramago.

The discovery was only possible due to the collaboration between researchers from an experimental RNA laboratory and scientists from the bioinformatics area, who worked together to characterize the proteins. The construction of the three-dimensional model of the nsp14-nsp10 complex was based on the equivalent SARS-Cov-1 proteins. "It's like doing a facial composite", says bioinformatician Caio Souza, who built the model. With a very clear notion of the shape of the protein, it was possible to predict the most important amino acids. "We have a very detailed map of the target we must attack with future therapies," points out Diana Lousa, fellow bioinformatician and co-author of the study. "By silencing this protein, we will be able to "domesticate" a severe disease and turn it into a cold," explains Cecilia Arraiano, leader of one of the two laboratories involved. "It's as if we turned a wolf into a dog."

This knowledge can now be used to develop antivirals, research which is now being carried out by the team. "Even with the hope of vaccines, it is essential to identify therapies capable of treating the infections that will continue to occur," explains Cláudio M. Soares, Director of ITQB NOVA and co-author of the work. "This type of research must be funded by public institutions," he adds. The scientific paper has been accepted for publication by the Federation of European Biological Societies (FEBS) in "The FEBS Journal".

Credit: 
Instituto de Tecnologia Química e Biológica António Xavier da Universidade NOVA de Lisboa ITQB NOVA

Approved medications preserve platelets and protect mice from bacterial blood infections

A study of 49 patients reveals that toxins from the bacterial pathogen Staphylococcus aureus can destroy the body's blood-clotting platelets, raising the risk of death during bacterial blood infections. Further experiments in mice also showed that the approved drugs ticagrelor and oseltamivir protected platelets and helped treat infections, suggesting these compounds could be repurposed into badly needed therapies for blood infections. Bacterial blood infections have mortality rates as high as 20% to 30% even with supportive care, and these rates have remained high for decades. Blood infections can also cause complications such as sepsis and endocarditis, and the rise of multidrug resistance has only compounded what was already a serious threat to public health. Infections with S. aureus are particularly difficult to treat, as the bacteria possess a range of tricks and defense mechanisms that allow them to evade or resist immune cells and antibiotics. While studying 49 patients with S. aureus blood infections, Josh Sun and colleagues discovered that many patients who succumbed showed abnormally low counts of platelets - small blood-clotting cells that can also combat infections. Follow-up experiments showed that S. aureus targeted platelets by secreting a toxin that destroyed platelet proteins, and by accelerating the clearance of platelets through the Ashwell-Morell receptor on liver cells. However, the approved blood thinner ticagrelor and the flu antiviral oseltamivir both protected platelets from the toxin-induced clearance in mice with S. aureus blood infections and improved survival. Sun et al. speculate that these drugs, if repurposed, could be combined with platelet infusions to further restore and protect platelet counts in ailing patients.

Credit: 
American Association for the Advancement of Science (AAAS)

Exploiting cancer cells to aid in their own destruction

Immunotherapy, which recruits the body's own immune system to attack cancer, has given many cancer patients a new avenue to treat the disease.

But many cancer immunotherapy treatments can be expensive, have devastating side effects, and only work in a fraction of patients.

Researchers at the Pritzker School of Molecular Engineering at the University of Chicago have developed a new therapeutic vaccine that uses a patient's own tumor cells to train their immune system to find and kill cancer.

The vaccine, which is injected into the skin just like a traditional vaccine, stopped melanoma tumor growth in mouse models. It even worked long-term, destroying new tumors long after the therapy was given.

The results were published March 24 in the journal Science Advances.

"This is a new strategy for immunotherapy," said Prof. Melody Swartz, who led the research. "It has the potential to be more efficacious, less expensive and much safer than many other immunotherapies. It is truly personalized medicine that has the potential to overcome many issues that arise with other treatments."

Recruiting a broad immune response

In many ways, the vaccine works like a traditional flu vaccine: it uses a less-potent version of the pathogen (here, a patient's own cancer cells, which are lethally irradiated before injection) to train the immune system to fight the disease.

However, rather than a preventive measure, this is a therapeutic vaccine, meaning it activates the immune system to destroy cancer cells anywhere in the body. To create it, Swartz and her team used melanoma cells from mice and then engineered them to secrete vascular endothelial growth factor C (VEGF-C).

VEGF-C causes tumors to strongly associate with the body's lymphatic system, which is normally considered bad for the patient, since it can promote metastasis. But the team recently found that when tumors activate surrounding lymphatic vessels, they are much more responsive to immunotherapy and promote "bystander" T cell activation, leading to a more robust and long-lasting immune response.

The team then had to figure out how to harness the benefits of lymphatic activation in a therapeutic strategy while avoiding the potential risks of metastasis.

'Training' the immune system

Maria Stella Sasso, a postdoctoral fellow and first author of the paper, tested many different strategies before settling on the vaccine approach, which allowed immune "training" in a site distant from the actual tumor.

The strategy of using a patient's own irradiated tumor cells in a therapeutic vaccine had previously been established by Glenn Dranoff and colleagues at the Novartis Institutes for BioMedical Research. Dranoff and team developed GVAX, a cancer vaccine that has been shown safe in clinical trials. Sasso decided to try this approach with VEGF-C rather than the cytokine used in GVAX. She dubbed the strategy "VEGFC-vax."

After engineering the cells to express VEGF-C, the research team irradiated them, so they would die within a few weeks. When they injected the cells back into the skin of mice, they found that the dying tumor cells could attract and activate the immune cells, which then could recognize and kill the actual tumor cells growing on the opposite side of the mouse. Since each tumor has its own unique signature of hundreds of molecules that the immune system can recognize, the vaccine promoted a broad, robust immune response.

That led to the prevention of tumor growth in all of the mice. It also led to immunological memory, preventing new tumor growth when tumor cells were re-introduced 10 months later.

"This shows that the therapy may provide long-term efficacy against metastasis and relapse," said Swartz, William B. Ogden Professor of Molecular Engineering.

Potential therapy for many types of cancers

Conceptually, this is the first strategy to exploit the benefits of local lymphatic vessel activation for more robust and specific immune response against tumor cells.

Unlike immunotherapeutic strategies that stimulate the immune system in a general way, such as checkpoint blockade or the many cytokines currently in preclinical development, this new immunotherapy activates only tumor-specific immune cells. Theoretically, this would avoid common side effects of immune stimulants, including immunotoxicity and even death.

And while many other cancer immunotherapies, such as CAR-T cell therapy, are tumor-specific, these strategies only work against tumor cells that express specific pre-identified tumor markers called antigens. Cancer cells can eventually overcome such treatments by shedding these markers or mutating, for example.

VEGFC-vax, however, can train immune cells to recognize a large number and variety of tumor-specific antigens. More importantly, these antigens do not need to be identified ahead of time.

The researchers are working to test this strategy on breast and colon cancers and think it could theoretically work on any type of cancer. They hope to ultimately take this therapy to clinical trials.

"We think this has huge promise for the future of personalized cancer immunotherapy," Swartz said.

Credit: 
University of Chicago

Vaccine science and side effects: How news messages affect views on vaccination

News coverage of expert scientific evidence on vaccine safety is effective at increasing public acceptance of vaccines, but the positive effect is diminished when the expert message is juxtaposed with a personal narrative about real side effects, new research has found.

The study, by researchers affiliated with the Annenberg Public Policy Center (APPC) of the University of Pennsylvania and the University of Illinois, tested the effects of messages about vaccination in televised news reports. These included video clips of Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, talking about evidence supporting the value and safety of the MMR (measles, mumps and rubella) vaccine, and a mother who's refusing to vaccinate her youngest child because her middle child, who is shown with a rash, had what she characterized as severe reactions after receiving the MMR vaccine.

The research, published in PLOS ONE, is based on an experiment with a nationally representative sample of 2,345 participants during the 2019 U.S. measles outbreak.

The study, "The Effects of Scientific Messages and Narratives About Vaccination," found that:

Fauci's "science-supporting" message had significant positive effects on views about vaccination when compared with a control message. Participants exposed to the expert message had lower perceptions of risk from vaccination; stronger pro-vaccine policy views; and stronger intentions to send a pro-vaccine letter to a state representative and to encourage other people to vaccinate their children.

The "hesitancy-inducing" narrative by the mother had no significant effect by itself on these outcomes.

But when the two messages were juxtaposed, with video of the mother preceding Fauci, the mother's hesitancy narrative diminished the effectiveness of the pro-vaccine message, according to some measures.

"In this paper," the authors write, "we treated parental reports of potentially real side effects as Hesitancy-Inducing Narratives because, even when accurate, their portrayal in media can lead to overgeneralization and fuel vaccine hesitancy by leading the public to draw inaccurate inferences about the prevalence and severity of side effects. In short, individual cases of vaccine side effects, even if true, may elicit false inferences, and the media's reliance on dramatic and vivid cases may lead to overestimation of risks that are relatively rare."

The research

The experiment was conducted from February 28-March 18, 2019, during the largest U.S. measles outbreak in over a quarter-century. "We often wondered about stories of vaccine side effects - like the concerns we've heard recently with the COVID-19 vaccines," said lead author Ozan Kuru, who worked on the study as a postdoctoral fellow at APPC and is now an assistant professor in the Department of Communications and New Media at the National University of Singapore. "Do those stories have negative effects on support for vaccines, and how do we ensure that people have an accurate understanding of the science?"

Prior research has failed to simulate the actual news environment by assessing the effects of exposure both to experts' messages about the value of vaccination and to personal accounts of the reasons for vaccination hesitance that discuss actual but relatively rare side effects.

According to the Centers for Disease Control and Prevention (CDC), "soreness, redness or rash where the shot is given and rash all over the body can happen after MMR vaccine," while "more serious reactions happen rarely," including seizures, temporary pain and stiffness in the joints, pneumonia, and swelling of the brain and/or spinal cord covering. "As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury or death."

The researchers said, "This dual aspect of vaccine side effects - their rare existence and people's tendency to overgeneralize from individual stories - places their portrayal in the media in what we consider a gray zone between accurate and misleading information. We thus posit that media coverage of such stories without proper contextualization can be misleading and has the potential to influence public opinion."

Vaccine videos

In this experiment, the researchers used edited videos from televised news coverage with the network identification removed. The 2,345 participants were randomly assigned to view one of six short, edited video clips:

(1) the mother's "hesitancy-inducing" narrative;

(2) Fauci's expert, "science-supporting" statistics-heavy video;

(3) a "science-supporting" video of parents whose children would be endangered if exposed to measles but could not get the vaccine for other health reasons or who had caught measles and experienced complications;

a combination of the mother's narrative (1) and Fauci (2);

a combination of the mother's narrative (1) and the other parents (3);

a control video about the benefits of aspirin.

After watching the videos, the participants answered questions about vaccine risk, support for pro-vaccine policies, their intentions to encourage parents to vaccinate their children, and whether they would agree to send a pro-vaccine letter to a state representative.

On the findings

Contrary to the researchers' initial hypothesis, the mother's "hesitancy-inducing" narrative did not by itself affect outcomes - which, the authors say, is "generally consistent with research suggesting that exposure to single messages rarely produced an impact." However, the fact that it lessened the positive effects of the Fauci video raises concerns and invites further study.

"It might be that when we hear the mother's narrative in isolation, we don't make a big deal of it," said co-author Dolores Albarracín, a professor of psychology and business administration at the University of Illinois at Urbana-Champaign and a distinguished research fellow at APPC. "But when people subsequently hear about the science, it prompts them to think about vaccines, they recall the mom, and this leaves them haunted by doubts."

Kathleen Hall Jamieson, a co-author and director of the Annenberg Policy Center, noted that Fauci is delivering an unconditional "it's safe" message about the MMR vaccine. "Nothing the mother says is inaccurate," Jamieson said. "We assume that exposure to her story and visualized evidence of her rash-ridden older child calls into question Dr. Fauci's categorical assertions about the safety of the vaccine."

The "science-supporting" video from the parents was found to be relatively ineffective compared with Fauci's message.

Implications for COVID-19 messaging

The researchers said the findings have important implications for public health messaging and newsroom decisions about coverage of COVID-19 vaccines.

"We are not recommending that the media stop reporting about vaccine safety and side effects," Albarracín said. "But our recommendation is that statistical information about vaccine trials should be communicated to the public repeatedly and early, before vivid narratives of side effects take hold."

Jamieson added, "The scientific community needs to remind the public that the benefits of using approved vaccines outweigh the risks - and that the risks associated with contracting the disease are substantially higher than any associated with the vaccine."

Credit: 
Annenberg Public Policy Center of the University of Pennsylvania

Shining a healing light on the brain

image: Artist's rendering shows X-rays striking radioluminescent nanoparticles in the brain, which emit red light that triggers a sodium (Na+) and potassium (K+) ion influx and thereby activates brain neurons.

Image: 
(Image by Zhaowei Chen/Argonne National Laboratory.)

Scientists make pivotal discovery of method for wireless modulation of neurons with X-rays that could improve the lives of patients with brain disorders. The X-ray source only requires a machine like that found in a dentist’s office.

Many people worldwide suffer from movement-related brain disorders. Epilepsy accounts for more than 50 million; essential tremor, 40 million; and Parkinson’s disease, 10 million.

Relief for some brain disorder sufferers may one day be on the way in the form of a new treatment invented by researchers from the U.S. Department of Energy’s (DOE) Argonne National Laboratory and four universities. The treatment is based on breakthroughs in both optics and genetics. It would be applicable to not only movement-related brain disorders, but also chronic depression and pain.

“Our high precision noninvasive approach could become routine with the use of a small X-ray machine, the kind commonly found in every dental office.” — Elena Rozhkova, a nanoscientist in Argonne’s Center for Nanoscale Materials

This new treatment involves stimulation of neurons deep within the brain by means of injected nanoparticles that light up when exposed to X-rays (nanoscintillators) and would eliminate an invasive brain surgery currently in use. 

“Our high-precision noninvasive approach could become routine with the use of a small X-ray machine, the kind commonly found in every dental office,” said Elena Rozhkova, a lead author and a nanoscientist in Argonne’s Center for Nanoscale Materials (CNM), a DOE Office of Science User Facility.

Traditional deep brain stimulation requires an invasive neurosurgical procedure for disorders when conventional drug therapy is not an option. In the traditional procedure, approved by the U.S. Food and Drug Administration, surgeons implant a calibrated pulse generator under the skin (similar to a pacemaker). They then connect it with an insulated extension cord to electrodes inserted into a specific area of the brain to stimulate the surrounding neurons and regulate abnormal impulses.

“The Spanish-American scientist José Manuel Rodríguez Delgado famously demonstrated deep brain stimulation in a bullring in the 1960s,” said Vassiliy Tsytsarev, a neurobiologist from the University of Maryland and a co-author of the study. “He brought a raging bull charging at him to a standstill by sending a radio signal to an implanted electrode.”

About 15 years ago, scientists introduced a revolutionary neuromodulation technology, “optogenetics,” which relies on genetic modification of specific neurons in the brain. These neurons create a light-sensitive ion channel in the brain and, thereby, fire in response to external laser light. This approach, however, requires very thin fiberoptic wires implanted in the brain and suffers from the limited penetration depth of the laser light through biological tissues.

The team’s alternative optogenetics approach uses nanoscintillators injected in the brain, bypassing implantable electrodes or fiberoptic wires. Instead of lasers, they substitute X-rays because of their greater ability to pass through biological tissue barriers.

“The injected nanoparticles absorb the X-ray energy and convert it into red light, which has significantly greater penetration depth than blue light,” said Zhaowei Chen, former CNM postdoctoral fellow.

“Thus, the nanoparticles serve as an internal light source that makes our method work without a wire or electrode,” added Rozhkova. Since the team’s approach can both stimulate and quell targeted small areas, Rozhkova noted, it has other applications than brain disorders. For example, it could be applicable to heart problems and other damaged muscles.    

One of the team’s keys to success was the collaboration between two of the world-class facilities at Argonne: CNM and Argonne’s Advanced Photon Source (APS), a DOE Office of Science User Facility. The work at these facilities began with the synthesis and multi-tool characterization of the nanoscintillators. In particular, the X-ray excited optical luminescence of the nanoparticle samples was determined at an APS beamline (20-BM). The results showed that the particles were extremely stable over months and upon repeated exposure to the high-intensity X-rays.

According to Zou Finfrock, a staff scientist at the APS 20-BM beamline and Canadian Light Source, “They kept glowing a beautiful orange-red light.”

Next, Argonne sent CNM-prepared nanoscintillators to the University of Maryland for tests in mice. The team at University of Maryland performed these tests over two months with a small portable X-ray machine. The results proved that the procedure worked as planned. Mice whose brains had been genetically modified to react to red light responded to the X-ray pulses with brain waves recorded on an electroencephalogram.

Finally, the University of Maryland team sent the animal brains for characterization using X-ray fluorescence microscopy performed by Argonne scientists. This analysis was performed by Olga Antipova on the Microprobe beamline (2-ID-E) at APS and by Zhonghou Cai on the Hard X-ray Nanoprobe (26-ID) jointly operated by CNM and APS.

This multi-instrument arrangement made it possible to see tiny particles residing in the complex environment of the brain tissue with a super-resolution of dozens of nanometers. It also allowed visualizing neurons near and far from the injection site on a microscale. The results proved that the nanoscintillators are chemically and biologically stable. They do not wander from the injection site or degrade.

“Sample preparation is extremely important in these types of biological analysis,” said Antipova, a physicist in the X-ray Science Division (XSD) at the APS. Antipova was assisted by Qiaoling Jin and Xueli Liu, who prepared brain sections only a few micrometers thick with jeweler-like accuracy.

“There is an intense level of commercial interest in optogenetics for medical applications,” said Rozhkova. “Although still at the proof-of-concept stage, we predict our patent-pending wireless approach with small X-ray machines should have a bright future.”

The related article “Wireless optogenetic modulation of cortical neurons enabled by radioluminescent nanoparticles” appeared in ACS Nano. In addition to Rozhkova, Chen, Finfrock, Antipova and Cai, another Argonne author is Rosemarie Wilton. University contributors include Vassiliy Tsytsarev, Dongyi Wang, Yi Liu, Brandon Gaitan, Yang Tao and Yu Chen from the University of Maryland, Department of Bioengineering; Hiroyuki Arakawa and Reha Erzurumlu from the University of Maryland School of Medicine; Fritz Lischka from the Uniformed Services University of the Health Sciences; Bryan Hooks from the University of Pittsburgh, Department of Neurobiology; and Huanghao Yang from Fuzhou University.

Credit: 
DOE/Argonne National Laboratory

Group testing method developed for COVID-19

image: Fig. 1. Sample of swab grouping with transposition-based replication

Image: 
Mario R. Guarracino et al.

Researchers Mario Guarracino the HSE Laboratory of Algorithms and Technologies for Networks Analysis in Nizhny Novgorod and Julius ?ilinskas and Algirdas Lančinskas from Vilnius University, have proposed a new method of testing for COVID-19. This group method allows results to be obtained 13 times faster as compared to individual testing of each sample. The research paper was published in the journal Scientific Reports.

The COVID-19 pandemic has already affected millions of people from over 200 countries. The rapid virus expansion demonstrated how fast such infections can spread in today's globalized world. At the beginning of the pandemic, when little was known about the virus and vaccines had not yet been developed, it was possible to slow its spread only by means of limiting the population's mobility. Almost everyone around the world went through various lockdowns and periods of isolation. If large groups of people can be tested quickly, the restrictions can be less strict and more effective at the same time, believe the authors of the paper 'Pooled testing with replication as a mass testing strategy for the COVID-19 pandemics.'

Present COVID-19 testing solutions are based on the extraction of RNA from patients using oropharyngeal and nasopharyngeal swabs, and then testing with real?time PCR for the presence of specific RNA filaments identifying the virus. The speed of this approach is limited by the availability of reactants, trained technicians and laboratories.

One way to speed up the testing procedures is group testing, where the swabs of multiple patients are grouped together and tested. The swabs from groups that return a positive result are then tested individually in order to detect specific COVID-19 positive patients. This approach helps decrease the number of tests twofold or more (depending on the spread of the disease) as compared to individual testing of each swab.

For example, suppose 96 samples should be tested and pools of up to 12 samples are possible. In individual testing, 96 tests are necessary. In pool testing, 8 pools of 12 samples are taken and testing is performed. If the result of one pool is positive, then additional 12 individual tests are needed. If two or three groups return a positive result, 24 or 36 additional tests are required, which, together with the first eight tests, will mean a decrease in the number of tests from two to five times as compared to individual testing.

The researchers believe that the number of tests can be decreased by optimizing the size of groups that takes into account the total number of swabs and the forecasted number of infected individuals. As the number of infected individuals increases, the possibility of saving swabs decreases but is still about 40% in the event of an incidence of 100 positive samples per 1,000, and 18% for an incidence of 200 per 1,000.

There are ways to optimize group testing, such as choosing the optimal group size based on the total number of swabs and the projected level of disease spreading. Another is the binary splitting method, in which a positive group is split into halves and is tested again, until individual positive swabs are detected. The second method, however, is very time-consuming, which decreases its attractiveness during a pandemic.

In addition, to optimize group testing, transposition-based replication is used: after grouping the swabs, researchers form additional control groups from the same swabs and test them together with the main groups. This helps further cut the number of tests, and if the disease levels are low, it also helps to detect positive swabs in one step, which speeds up the testing considerably.

However, this method does not allow for experimenting with group sizes to detect the optimal group size under specific conditions. Researchers from HSE University and Vilnius University suggested OptReplica technology, which uses a more complicated algorithm of swab grouping in key and control groups and helps decrease the number of control groups. In addition, the algorithm helps calculate the optimal group size for the present number of swabs and the forecasted level of disease spreading.

The authors conducted experimental research on samples of 96 and 384 swabs, carrying out 100 randomized tests for each sample size, and compared the effectiveness of transposition-based replication and OptReplica method for different levels of disease incidence. The studies have shown that if the optimal size of groups is chosen, OptReplica is more effective than transposition-based replication. In cases with low incidence, the use of OptReplica, a 13x average reduction of tests can be achieved compared to individual testing without time delay.

'Our simulations are actually proving that using this optimization replication strategy is always advantageous and, even in case of high spread of the disease (10% or 20% of positives in the population), we are still competitive with individual testing strategy', explained Mario Guarracino, Chief Research Fellow of the Laboratory of Algorithms and Technologies for Networks Analysis.

The authors of the new technology suggest using it for asymptomatic populations with seemingly low incidence of coronavirus cases, where it will help detect the infected individuals at a maximum speed with a minimum number of tests, and timely apply the quarantine measures in order to prevent spreading of the disease. In regions with disease incidents over 50 cases per 1,000 tests, the authors suggest using other methods of group replication, or testing without replication.

Credit: 
National Research University Higher School of Economics

Zooming in on muscle cells

video: 3D arrangement of thin and thick filaments and the cross-bridges within a sarcomere.

Image: 
@MPI of Molecular Physiology

An old technique flexes its muscles

Sarcomeres are small repeating subunits of myofibrils, the long cylinders that bundle together to make the muscle fibres. Inside the sarcomeres, filaments of the proteins myosin and actin interact to generate muscle contraction and relaxation. So far, traditional experimental approaches to investigate the structure and function of muscle tissue were performed on reconstructed protein complexes or suffered from low resolution. "Electron cryo-tomography, instead, allows us to obtain detailed and artefact-free 3D images of the frozen muscle", says Raunser.

Cryo-ET was for a long time an established yet niche methodology. But recent technical advances in electron cryo-microscopy (cryo-EM) as well as the new development of cryo focused ion beam (FIB) milling are pushing cryo-ET resolution. Similar to cryo-EM, researchers flash-freeze the biological sample at a very low temperature (- 175 °C). Through this process, the sample preserves its hydration and fine structure and remains close to its native state. FIB milling is then applied to shave away extra material and obtain an ideal thickness of around 100 nanometers for the transmission electron microscope, which acquires multiple images as the sample is tilted along an axis. Finally, computational methods reconstruct a three-dimensional picture at high resolution.

Raunser's team performed cryo-ET on mouse myofibrils isolated at the King's College, and obtained a resolution of one nanometer (a millionth of a millimetre, enough to see fine structures within a protein): "We can now look at a myofibril with details thought unimaginable only four years ago. It's fascinating!", says Raunser.

Fibres in their natural context

The calculated reconstruction of the myofibrils revealed the three-dimensional organisation of the sarcomere, including the sub regions M-, A-, and I- bands, and the Z-disc, which unexpectedly forms a more irregular mesh and adopts different conformations. The scientists used a sample with myosin strongly bound to actin, representing a stage of the contracting muscle that is called the rigor state. And indeed, they could visualise for the first time in the native cell how two heads of the same myosin bind to an actin filament. They also discovered that the double head not only interacts with the same actin filament but is also found split between two actin filaments. This has never been seen before and shows that proximity to the next actin filament is stronger than the cooperative effect between the neighbouring heads.

"This is just the beginning. Cryo-ET is moving from niche to widespread technology in structural biology", says Raunser. "Soon we will be able to investigate muscle diseases at molecular and even atomic level". Mouse muscles are very similar to those of humans, yet scientists plan to investigate muscle tissue from biopsies or derived from pluripotent stem cells.

Credit: 
Max Planck Institute of Molecular Physiology

Decline in black cherry regeneration may herald wider forest change

image: A team of USDA Forest Service scientists explored five hypotheses for decline in black cherry regeneration: climate change, deer browsing, senescence, pathogens, and reduced nitrogen availability. They found that the most likely factors are pathogens and reduced nitrogen availability, and that black cherry may actually be a story of change on a much bigger scale.

Image: 
USDA Forest Service photograph

In the heart of black cherry's native range, including a part of the Allegheny Hardwoods that bills itself as the "Black Cherry Capital of the World," the tree's regeneration, growth and survival have all been declining for more than a decade. In a new analysis, a team of USDA Forest Service and University of Missouri scientists identify likely factors behind the tree's decline and, more significantly, conclude that black cherry may be the tip of the iceberg in terms of change in eastern deciduous forests.

Scientists used a combination of synthesis of existing research and new analyses to examine the leading hypotheses for black cherry's regeneration failure. They conclude that the two factors that are most likely contributing to declining abundance of black cherry are an increase in pathogens and less nitrogen deposition in soil.

"We began this project wanting to narrow down the potential drivers behind the change in black cherry; what we found is that this may be a story of change on a much bigger scale, with mixed species forests in the coming century likely to reflect the response of many individual tree species to changing environmental conditions, biotic stressors, and their interactions," said Alejandro Royo, a research ecologist with the Northern Research Station and the study's lead author.

Credit: 
USDA Forest Service - Northern Research Station